OBJECTIVE: To investigate whether the dietary phytochemical, indole-3-carbinol (I3C), in¯uences the level of estradiol 2-hydroxylation in obese women. DESIGN: A clinical intervention study involving the ingestion of puri®ed I3C, 400 mg, for two months. SUBJECTS: Five healthy, overweight, premenopausal women (age: 35±47 y, body mass index (BMI): 27±53 kg/m 2 ). MEASUREMENTS: Two estrogen metabolites, 2-hydroxyestrone (2OHE1) and estriol (E3), were measured by radioimmunoassay in untimed overnight urine samples, before and after ingestion of I3C. RESULTS: The ratio of urinary estrogens, 2OHE1/E3, was signi®cantly increased in obese women following I3C, re¯ecting induction of 2-hydroxylation in these women. CONCLUSIONS: Obese premenopausal women experience increased estrogen 2-hydroxylation in response to the dietary agent, I3C, similar to non-obese women. This response to I3C may result in a hormonal milieu that helps reduce estrogen-dependent cancer risk.
Introduction
Obesity adversely affects various hormonal processes, including estrogen bioavailability. These changes increase the risk of hormone-dependent diseases such as breast and endometrial cancer among postmenopausal women. 1 Obesity ampli®es the actions of estrogens through at least three mechanisms. First, production of estrogens is augmented as a result of greater aromatization of adrenal androgens in adipocytes. 2 Second, concentrations of sex hormone-binding globulin are markedly reduced, increasing the unbound estrogen component and making circulating estrogens more available for uptake in tissues. 3, 4 Third, obesity suppresses the oxidative catabolism of estrogens, 5 thereby decreasing the formation of inactive 2-hydroxyestrone (2OHE1), and enhancing the production of potentially carcinogenic 16a-hydroxyestrogens, 16a-hydroxyestrone (16OHE1) and estriol (E3).
C-2 and C-16 oxidations are competing metabolic pathways, the relative strengths of which can be approximated by measuring two urinary estrogen metabolites, 2OHE1 and E3. 6 We have presented evidence that the ratio of urinary 2OHE1/E3 serves as a potential biomarker of breast cancer risk. 7, 8 For example, factors that decrease C-2 and/or increase C16a metabolism are associated with higher breast cancer rates.
The cancer-promoting effects of obesity might be decreased by reversing the physiological changes described above. We have discovered that the phytochemical, indole-3-carbinol (I3C), a constituent of cabbage-family vegetables, strongly increased estrogen 2-hydroxylation in non-obese women. 7, 9 This effect might explain the breast-protective effect of dietary fruits and vegetables. 10, 11 In this paper, we examine whether I3C enhances estrogen 2-hydroxylation in obese women.
Materials and methods
Obese subjects were recruited locally and each provided informed consent. Participants were excluded for any medical condition, medication, or dietary or lifestyle habit that might interfere with estrogen metabolism, such as hyperthyroidism, l-thyroxine, vegetarian diet, or cigarette smoking. 12 We recruited ®ve premenopausal subjects (average age AE s.d. 40.8 AE 5.1 y, range 35±47). Each had normal clinical chemistries and a regular menstrual cycle, and had a body-mass index (BMI) greater than 27 (mean 37.1 AE 9.8 kg/m 2 , range 27.5±53.6). The I3C used in this study was generously provided by Dr William Hennen (Enrich International, Orem, UT). I3C was free of impurities (b 98%) based on GC-MS analysis.
Initially, untimed overnight urine samples were obtained from each individual during the ®rst seven days of their menstrual cycle. Urine aliquots with 0.1% sodium ascorbate were stored at 720 C. Sub-jects then began taking 400 mg of I3C each day throughout the next two menstrual cycles. Additional urine samples were similarly obtained with the onset of each menses and processed identically. All urinary estrogen assays for an individual were conducted together (Pre-I3C, Post-I3C-1 and Post-I3C-2). During the study, women maintained their normal diets, and no adverse side effects were reported during ingestion of I3C. Previously published data 7 from an earlier placebocontrolled study of I3C in non-obese premenopausal women are included for comparison (see below). Urinary 2-hydroxyestrone (2OHE1) and estriol (E3) were measured by a radioimmunoassay procedure as described previously. 6, 13 Statistical analyses (2-tailed t tests) were performed using SPSS for Windows. Figure 1 shows the changes in the ratios of urinary 2OHE1/E3 for the ®ve obese subjects over the two months of the study. Pre-I3C values (mean AE s.d.) for the group averaged 0.38 AE 0.13, signi®cantly less than baseline values for a comparable non-obese population (see below). After one month (Post-I3C-1), average 2OHE1/E3 ratios nearly doubled to 0.67 AE 0.21, and this increase was maintained (0.69 AE 0.20) after an additional month of I3C administration (Post-I3C-2). Both increases in 2OHE1/E3 were statistically signi®cant (P`0.02). The average increase in 2OHE1/E3 for the ®ve participants in the ®rst month of I3C was 82% (95% con®dence interval (CI) 24±105%), and the average increase in the second month was 93% (95% CI 15±114%).
Results
Changes in urinary 2OHE1/E3 in the obese subjects over two months are summarized in Table 1 , along with comparable urinary estrogen data obtained from a group of 20 non-obese premenopausal women. Average pre-I3C values for obese women (0.38 AE 0.13) were signi®cantly lower than those of non-obese women (0.72 AE 0.31, P 0.027). Post-I3C 2OHE1/E3 ratios of obese women were statistically indistinguishable from pre-I3C values of non-obese women.
Discussion
We have demonstrated that urinary 2OHE1/E3 ratios are suppressed in premenopausal obese women, con®rming earlier in vivo radiometric studies. 5 The current study was performed using polyclonal antisera, 6 and newer ELISA techniques with monoclonal antibodies have also documented signi®cantly lower C-2/ C-16a ratios in obese women.
14 Despite lower baseline values, I3C increased 2OHE1/E3 in the obese subjects into the non-obese range. The average increase in 2OHE1/E3 by I3C was 82±93%, although some individuals are clearly less responsive to the agent. This variable response to I3C was also observed among non-obese subjects. 7 We recently employed gas chromatography-mass spectrometry to simultaneously measure 13 urinary estrogens in non-obese women before and after I3C, and found that I3C not only increased 2-hydroxylation, but also lowered urinary concentrations of estradiol, estrone, estriol and 16a-hydroxyestrone. 15 The present data indicate that I3C similarly affects obese women. Lower urinary levels presumably re¯ect decreased formation of these estrogenic compounds in vivo. Such a ®nding suggests that I3C may help reduce estrogen-dependent carcinogenicity linked to obesity.
I3C is one of many phytochemicals under investigation as potential chemopreventive agents. 16 It stimulates cytochrome P450 IA-dependent catabolism of endogenous as well as exogenous compounds, and its safety in humans derives from the fact that it activates both phase I (for example, P450) and phase II (for example, drug conjugating) pathways. 16±18 Many of these chemopreventive compounds are present in a Figure 1 Changes in urinary 2-hydroxyestrone/estriol (2OHE1/ E3) before (Pre-I3C) and after one month (Post-I3C-1) and two months (Post-I3C-2) of oral indole-3-carbinol (I3C) in ®ve premenopausal obese women. diet rich in fruits and vegetables. Further research will be needed to determine the extent to which I3C alone can reverse the cancer-promoting effects of estrogen, and whether I3C can help reduce breast cancer risk among obese and normal-weight women.
